(Q47702753)

4 February 2018

title

Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency (English)

1 reference

4 February 2018

author name string

R Meierhenrich

1

1 reference

4 February 2018

J Carlsson

2

1 reference

4 February 2018

E Seifried

3

1 reference

4 February 2018

E Pfarr

4

1 reference

4 February 2018

A Smolarz

5

1 reference

4 February 2018

K L Neuhaus

6

1 reference

4 February 2018

U Tebbe

7

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

4 February 2018

International Journal of Cardiology

published in

1 reference

4 February 2018

volume

65

1 reference

4 February 2018

issue

1

1 reference

4 February 2018

page(s)

57-63

1 reference

4 February 2018

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Kranken

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Thrombolytic therapy for acute myocardial infarction. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative S

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Usefulness of residual plasma fibrinogen after intravenous streptokinase for predicting delay or failure of reperfusion in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900100-4

7 January 2021

10.1016/S0167-5273(98)00100-4

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018